Telix Submits European Marketing Application for Brain Cancer Imaging Candidate TLX101-Px
TLX is trading near its 52-week low of $6.28 (1.1% above the low).
Summary
Telix Pharmaceuticals has submitted a Marketing Authorization Application in Europe for TLX101-Px, its brain cancer imaging candidate, aiming to address a critical unmet need in glioma diagnosis and treatment decision-making.
Key Events · Product Development and Regulatory · TLX
-
European MAA Submission
Telix submitted a Marketing Authorization Application (MAA) in Europe for TLX101-Px (F-FET), its glioma (brain cancer) imaging candidate.
-
Addresses Unmet Medical Need
The submission aims to provide widespread access to advanced brain imaging, currently limited to hospital-based production, to distinguish progressive or recurrent glioma.
-
Strategic Link to Therapy Program
TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate, TLX101-Tx, which is in Phase 3 trials.
-
U.S. NDA to Follow
The company is concurrently preparing the U.S. regulatory package, with the New Drug Application (NDA) submission for TLX101-Px to the FDA expected to follow the European filing.
Analysis · TLX · Life Sciences
This filing marks a significant regulatory milestone for Telix Pharmaceuticals, as it seeks to commercialize TLX101-Px for glioma imaging in Europe. The submission addresses a critical unmet need for consistent quality and access to advanced brain imaging, particularly for distinguishing recurrent glioma from treatment-related changes. This move is strategically important as TLX101-Px is also being developed as a companion diagnostic for their glioblastoma therapy candidate, TLX101-Tx, currently in Phase 3 trials. The company's ability to leverage aspects of its U.S. FDA package to expedite the European filing demonstrates efficiency in its regulatory strategy, especially as the stock trades near its 52-week low.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.8% of the 1026 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.78%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLX was trading at $6.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $6.28 to $30.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.